var data={"title":"Bicalutamide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bicalutamide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5740?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bicalutamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bicalutamide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141227\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Casodex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141228\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACH-Bicalutamide;</li>\n      <li>ACT Bicalutamide;</li>\n      <li>Apo-Bicalutamide;</li>\n      <li>Casodex;</li>\n      <li>Dom-Bicalutamide;</li>\n      <li>JAMP-Bicalutamide;</li>\n      <li>Mylan-Bicalutamide;</li>\n      <li>PHL-Bicalutamide;</li>\n      <li>PMS-Bicalutamide;</li>\n      <li>PRO-Bicalutamide;</li>\n      <li>RAN-Bicalutamide;</li>\n      <li>Sandoz-Bicalutamide;</li>\n      <li>Teva-Bicalutamide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141265\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antiandrogen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141231\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, metastatic:</b> Oral: 50 mg once daily (in combination with an LHRH analogue)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, locally-advanced, high recurrence risk (off-label use):</b> Oral: 150 mg once daily (as monotherapy) (McLeod 2006). Additional trials may be necessary to further define the role of bicalutamide in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141232\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2649929\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141233\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic impairment at treatment initiation:</i> Mild, moderate, or severe impairment: No dosage adjustment is necessary. Use with caution in patients with moderate-to-severe impairment; clearance may be delayed in severe impairment (based on a limited number of patients).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic impairment during treatment:</i> ALT &gt;2 times ULN or development of jaundice: Discontinue immediately.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141207\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Casodex: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141192\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141211\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Dose should be taken at the same time each day, either in the morning or in the evening. May be administered with or without food. Treatment for metastatic cancer should be started concomitantly with an LHRH analogue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104433\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141210\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, metastatic:</b> Treatment of stage D<sub>2</sub> metastatic prostate cancer (in combination with an LHRH agonist)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitation of use: Bicalutamide 150 mg daily is not approved for use alone or with other treatments</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25721949\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Locally-advanced prostate cancer (monotherapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7999083\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Casodex may be confused with Kapidex [DSC]</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Casodex [US, Canada, and multiple international markets] may be confused with Capadex brand name for propoxyphene/acetaminophen [Australia, New Zealand]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141199\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse reaction percentages reported as part of combination regimen with an LHRH analogue unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Cardiovascular: Peripheral edema (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Central nervous system: Pain (35%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Endocrine &amp; metabolic: Hot flash (53%), gynecomastia (9%; monotherapy [150 mg]: 38% to 73% [McLeod 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Gastrointestinal: Constipation (22%), nausea (15%), diarrhea (12%), abdominal pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Genitourinary: Mastalgia (6%; monotherapy [150 mg]: 39% to 85% [McLeod 2006]), pelvic pain (21%), hematuria (12%), nocturia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Infection: Infection (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain (25%), weakness (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Respiratory: Dyspnea (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&ge;2% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest pain (8%), hypertension (8%), angina pectoris (2% to &lt;5%), cardiac arrest (2% to &lt;5%), cardiac failure (2% to &lt;5%), coronary artery disease (2% to &lt;5%), edema (2% to &lt;5%), myocardial infarction (2% to &lt;5%), syncope (2% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (10%), paresthesia (8%), headache (7%), insomnia (7%), myasthenia (7%), anxiety (5%), chills (2% to &lt;5%), confusion (2% to &lt;5%), drowsiness (2% to &lt;5%), hypertonia (2% to &lt;5%), nervousness (2% to &lt;5%), neuropathy (2% to &lt;5%), depression (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (9%), diaphoresis (6%), alopecia (2% to &lt;5%), pruritus (2% to &lt;5%), xeroderma (2% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Weight loss (7%), hyperglycemia (6%), weight gain (5%), decreased libido (2% to &lt;5%), dehydration (2% to &lt;5%), gout (2% to &lt;5%), hypercholesterolemia (2% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dyspepsia (7%), anorexia (6%), flatulence (6%), vomiting (6%), dysphagia (2% to &lt;5%), hernia (2% to &lt;5%), melena (2% to &lt;5%), periodontal abscess (2% to &lt;5%), xerostomia (2% to &lt;5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary tract infection (9%), impotence (7%), difficulty in micturition (5%), urinary retention (5%), dysuria (2% to &lt;5%), urinary urgency (2% to &lt;5%), urinary incontinence (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Gastrointestinal carcinoma (2% to &lt;5%), rectal hemorrhage (2% to &lt;5%), skin carcinoma (2% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased liver enzymes (7%), increased serum alkaline phosphatase (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Herpes zoster (2% to &lt;5%), sepsis (2% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Ostealgia (9%), arthritis (5%), leg cramps (2% to &lt;5%), myalgia (2% to &lt;5%), neck pain (2% to &lt;5%), pathological fracture (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Cataract (2% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Polyuria (6%), hydronephrosis (2% to &lt;5%), increased blood urea nitrogen (2% to &lt;5%), increased serum creatinine (2% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (8%), pharyngitis (8%), flu-like symptoms (7%), bronchitis (6%), asthma (2% to &lt;5%), epistaxis (2% to &lt;5%), sinusitis (2% to &lt;5%), pneumonia (4%), rhinitis (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Cyst (2% to &lt;5%), fever (2% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Decreased glucose tolerance, decreased hemoglobin, decreased white blood cell count, hepatic failure, hepatitis, hepatotoxicity, hypersensitivity (including angioedema and urticaria), increased serum ALT, increased serum AST, increased serum bilirubin, interstitial pneumonitis, interstitial pulmonary disease (most often at doses &gt;50 mg), pulmonary fibrosis, skin photosensitivity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141214\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to bicalutamide or any component of the formulation; use in women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Patients with localized prostate cancer undergoing watchful waiting; children</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141196\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gynecomastia: May cause gynecomastia or breast pain at higher (off-label) doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic: Anemia may occur with testosterone suppression; monitor CBC periodically as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Rare cases of death or hospitalization due to severe liver injury have been reported (postmarketing); hepatotoxicity generally occurs within the first 3 to 4 months of use. Use with caution in moderate-to-severe hepatic dysfunction. Monitor transaminases (baseline and periodically); if clinical signs/symptoms suggestive of liver dysfunction occur, promptly monitor liver function tests; discontinue if patients have jaundice or ALT is &gt;2 times the upper limit of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Angioneurotic edema and urticaria have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interstitial lung disease: Has been reported rarely (including fatalities) although mostly at dosages greater than what is recommended; promptly evaluate any worsening of respiratory symptoms (eg, dyspnea, cough and fever).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Spermatogenesis: May lead to spermatogenesis inhibition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine 2010). Androgen deprivation therapy may cause prolongation of the QT/QTc interval (Garnick 2004); evaluate risk versus benefit in patients with congenital long QT syndrome, heart failure, frequent electrolyte abnormalities, and in patients taking medication known to prolong the QT interval. Correct electrolytes prior to initiation and consider periodic electrolyte and ECG monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone mineral density: Prolonged use of antiandrogen therapy is associated with decreased bone mineral density and an increased risk of osteoporosis and fracture (Smith 2003); alcohol abuse, familial history of osteoporosis, and/or chronic use of drugs capable of decreasing bone mass (eg, corticosteroids) may increase risk. Evaluate risk carefully before initiating therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: When used in combination with LHRH agonists, a loss of glycemic control and decrease in glucose tolerance has been reported in patients with diabetes; monitor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in moderate-to-severe impairment; undergoes extensive hepatic metabolism. Limited data suggests excretion may be delayed in severe impairment leading to further drug accumulation. Consider periodic monitoring of liver function with prolonged therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anti-androgen withdrawal syndrome: Discontinue use immediately if disease worsens; decreased prostate specific antigen (PSA) levels and/or clinical improvement may be observed in some patients when antiandrogen therapy is held due to worsening of disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298862\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218454\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9154&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Astemizole: Bicalutamide may increase the serum concentration of Astemizole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Bicalutamide may increase the serum concentration of Cisapride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terfenadine: Bicalutamide may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Bicalutamide may increase the serum concentration of Vitamin K Antagonists. Specifically, free concentrations of the vitamin K antagonists may be increased. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2874397\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Bicalutamide is contraindicated in women. Androgen receptor inhibition during pregnancy may affect fetal development. In addition, male fertility may be impaired. Males with female partners of reproductive potential should use effective contraception during therapy and for 130 days after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2874023\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if bicalutamide is present in breast milk. Use is contraindicated in women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141205\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodically monitor CBC, ECG, echocardiograms, serum testosterone, luteinizing hormone, and prostate specific antigen (PSA). Liver function tests should be obtained at baseline and repeated regularly during the first 4 months of treatment, and periodically thereafter; monitor for signs and symptoms of liver dysfunction. Monitor blood glucose in patients with diabetes. If initiating bicalutamide in patients who are on warfarin, closely monitor prothrombin time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141195\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Androgen receptor inhibitor; pure nonsteroidal antiandrogen that binds to androgen receptors; specifically a competitive inhibitor for the binding of dihydrotestosterone and testosterone; prevents testosterone stimulation of cell growth in prostate cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141213\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed; unaffected by food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 96%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic; glucuronidation and oxidation of the R (active) enantiomer to inactive metabolites; the S enantiomer is inactive</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Active enantiomer: ~6 days (~10 days in severe hepatic impairment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Active enantiomer: ~31 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine and feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141216\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bicalutamide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $550.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Casodex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $692.47</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141218\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Androdex (JO);</li>\n      <li>Bicadex (HR, PH);</li>\n      <li>Bical (BD);</li>\n      <li>Bicalan (EE);</li>\n      <li>Bicalox (NZ);</li>\n      <li>Bicalude (KR);</li>\n      <li>Bicamide (IL, LB);</li>\n      <li>Bicapros (PH);</li>\n      <li>Bicatero (TH);</li>\n      <li>Bicloc (EC);</li>\n      <li>Bidrostat (AR, LK, PY);</li>\n      <li>Bikalen (TR);</li>\n      <li>Bilumid (UA);</li>\n      <li>Biprosta (IN);</li>\n      <li>Bosconar (AR);</li>\n      <li>Bypro (HK, TW);</li>\n      <li>Calumid (MY, TH, VN);</li>\n      <li>Calumin (PH);</li>\n      <li>Calutex (AU);</li>\n      <li>Calutide (JO, LK);</li>\n      <li>Calutide-50 (IN);</li>\n      <li>Calutol (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Casodex (AE, AR, AT, BB, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CU, CY, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, HU, ID, IE, IL, IT, JM, JO, JP, KE, KR, KW, LB, LK, LR, LT, LU, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, PE, PH, PK, PL, PR, PT, QA, RO, RU, SC, SD, SE, SG, SI, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Cosamide (AU);</li>\n      <li>Cosudex (NZ);</li>\n      <li>Diproca (ID);</li>\n      <li>Gepeprostin (BR);</li>\n      <li>Kalumid (UA);</li>\n      <li>Kasodeks (UA);</li>\n      <li>Lutamidal (CL, PE, PY);</li>\n      <li>Procalut (TR);</li>\n      <li>Prosmide (LB);</li>\n      <li>Talum (SG);</li>\n      <li>Tosadex (TR);</li>\n      <li>Vicalud (KR);</li>\n      <li>Yonistib (RO);</li>\n      <li>Zolacos CP (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/25199761/pubmed\" target=\"_blank\" id=\"25199761\">25199761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bicalutamide [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals USA Inc; February 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casodex (bicalutamide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casodex (bicalutamide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garnick MB, Pratt CM, Campion M, et al. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix [abstract]. <i>J Clin Oncol</i>. 2004;22(14S):4578.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iversen, P, Johansson JE, Lodding P, et al, &ldquo;Bicalutamide (150 mg) Versus Placebo as Immediate Therapy Alone or as Adjuvant to Therapy With Curative Intent for Early Nonmetastatic Prostate Cancer: 5.3 Year Median Followup from the Scandinavian Prostate Cancer Group Study Number 6,&rdquo; <i>J Urol</i>, 2004, 172(5 Pt 1):1871-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,&rdquo; <i>Circulation</i>, 2010, 121:831-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/20124128/pubmed\" target=\"_blank\" id=\"20124128\">20124128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loblaw DA, Virgo KS, Nam R, et al, &ldquo;Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline,&rdquo; <i>J Clin Oncol</i>, 2007, 25(12):1596-605.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/17404365/pubmed\" target=\"_blank\" id=\"17404365\">17404365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLeod DG, Iversen P, See WA, et al, &ldquo;Bicalutamide 150 mg Plus Standard Care vs Standard Care Alone for Early Prostate Cancer,&rdquo; <i>BJU Int</i>, 2005, 97(2):247-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/16430622/pubmed\" target=\"_blank\" id=\"16430622\">16430622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16753373\"></a>McLeod DG, See WA, Klimberg I, et al, &ldquo;The Bicalutamide 150 mg Early Prostate Cancer Program: Findings of the North American Trial at 7.7-Year Median Followup,&rdquo; <i>J Urol</i>, 2006, 176(1):75-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/16753373/pubmed\" target=\"_blank\" id=\"16753373\">16753373</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schellhammer P, Sharifi R, Block N, et al, &ldquo;A Controlled Trial of Bicalutamide Versus Flutamide, Each in Combination With Luteinizing Hormone-Releasing Hormone Analogue Therapy, in Patients With Advanced Prostate Cancer. Casodex Combination Study Group.&rdquo; <i>Urology</i>, 1995, 45(5):745-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/7538237/pubmed\" target=\"_blank\" id=\"7538237\">7538237</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schellhammer PF, Sharifi R, Block NL, et al, &ldquo;Clinical Benefits of Bicalutamide Compared With Flutamide in Combined Androgen Blockade for Patients With Advanced Prostatic Carcinoma: Final Report of a Double-Blind, Randomized, Multicenter Trial. Casodex Combination Study Group,&rdquo; <i>Urology</i>, 1997, 50(3):330-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/9301693/pubmed\" target=\"_blank\" id=\"9301693\">9301693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. <i>Cancer</i>. 2003;97(3 Suppl):789-795.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/12548577/pubmed\" target=\"_blank\" id=\"12548577\">12548577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9154 Version 169.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F141227\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F141228\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F141265\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F141231\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F141232\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2649929\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F141233\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F141207\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F141192\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F141211\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104433\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F141210\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25721949\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7999083\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F141199\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F141214\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F141196\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298862\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218454\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2874397\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2874023\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F141205\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F141195\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F141213\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F141216\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F141218\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9154|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bicalutamide-patient-drug-information\" class=\"drug drug_patient\">Bicalutamide: Patient drug information</a></li></ul></div></div>","javascript":null}